Molecular Prognostic Assay for Early Stage Lung Cancer
The CLIA-certified Razor Genomics’ Molecular Prognostic Assay is helping to lead a revolution in the precision management of the world’s deadliest cancer. The assay, backed by the most extensive, blinded, independent validation studies published for any molecular prognostic in lung cancer, (1-4) provides patients who have undergone resection of non-squamous, non-small cell lung cancer and their doctors with the most accurate prognostic designation available into high-, intermediate- or low-risk of death within 5 years after operation.
Contact our CLIA-certified laboratory for more information on how to obtain the assay: (415) 769-4955
1. Kratz et al. Lancet 2012;379:823 2. Kratz et al. JAMA 2012;308:1629 3. Woodard et al. Clin Lung Cancer 2014:15:426 4. Woodard et al. Clin Lung Cancer 2017:epub
Predictive Assays for Lung Cancer using Next Generation Sequencing
7 Gene Lung Cancer Assay 17 Gene Lung Cancer Assay for China (CFDA Class 1 approved) 25 Gene Lung Cancer Assay
Precision Medicine: Identifying Patients’ Cancer-Driving Genomic Mutations and Matching Patients to Targeted Therapies and Clinical Trials
Razor Genomics’ innovative technology detects genomic mutations and provides oncologists with rapid, accurate and actionable information about their patients.
Razor Genomics’ products match patients with targeted therapies and clinical trials to dramatically improve patient outcomes.
Razor Genomics’ bioinformatics platform aggregates genomic information, advancing our understanding of the etiology and novel treatment targets for cancer.